Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome

ABSTRACT: Multicenter, multinational, randomized, 2-arm, double-blind, phase II clinical study with 2000mg mesalamine, or placebo for prevention of colorectal neoplasia in Lynch Syndrome patients during and following daily intake for 2 years.

DISEASE(S): Colon Neoplasm,Lynch Syndrome,Colon Cancer,Colorectal Cancer,Lynch Syndrome, Which Is Increasing The Risk Of Developing Colorectal Cancer.,Colorectal Neoplasms, Hereditary Nonpolyposis,Colonic Neoplasms

PROVIDER: 2380091 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR